Financial Survey: Tetralogic Pharmaceuticals Corp (TLOG) & Osiris Therapeutics (OSIR)
Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) and Osiris Therapeutics (NASDAQ:OSIR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.
Volatility & Risk
Tetralogic Pharmaceuticals Corp has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Comparatively, Osiris Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
This is a summary of recent recommendations for Tetralogic Pharmaceuticals Corp and Osiris Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetralogic Pharmaceuticals Corp||0||0||0||0||N/A|
This table compares Tetralogic Pharmaceuticals Corp and Osiris Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-73.81%|
Institutional and Insider Ownership
2.7% of Tetralogic Pharmaceuticals Corp shares are held by institutional investors. Comparatively, 19.9% of Osiris Therapeutics shares are held by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are held by insiders. Comparatively, 44.6% of Osiris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Tetralogic Pharmaceuticals Corp and Osiris Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-$21.14 million||($1.76)||-0.01|
|Osiris Therapeutics||$86.60 million||2.13||$4.41 million||N/A||N/A|
Osiris Therapeutics has higher revenue and earnings than Tetralogic Pharmaceuticals Corp.
Osiris Therapeutics beats Tetralogic Pharmaceuticals Corp on 5 of the 8 factors compared between the two stocks.
Tetralogic Pharmaceuticals Corp Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Osiris Therapeutics Company Profile
Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.
Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.